Radiopharm Theranostics Limited (RAD.AX)
| Previous close | 0.1550 |
| Open | 0.1650 |
| Bid | 0.1550 x N/A |
| Ask | 0.1750 x N/A |
| Day's range | 0.1550 - 0.1650 |
| 52-week range | 0.1000 - 0.2750 |
| Volume | |
| Avg. volume | 347,809 |
| Market cap | 52.537M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0600 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.47 |
- GlobeNewswire
Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceuticals
SYDNEY, Australia, March 03, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that through its wholly owned subsidiary, Radiopharm Theranostics (USA) Inc., it has entered into a binding agreement to acquire Pharma15 Corporation (Pharma15), a private US-based venture which is developing next-generation therapeutic radiopharmaceuticals for Prostate
- GlobeNewswire
Dr Ken Herrmann Appointed to RAD Scientific Advisory Board
SYDNEY, Australia, March 03, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the appointment of Dr Ken Herrmann to the Company’s Scientific Advisory Board (SAB). Dr Herrmann is a certified Nuclear Medicine physician who also holds an executive MBA from the University of Zürich and currently serves as Chair of the Departm
- GlobeNewswire
Radiopharm Theranostics Initiates Process for Nasdaq Listing
Proposed listing on NASDAQ with RADX ticker symbolForm 20-F registration filed with Securities and Exchange CommissionTrading expected to commence late March 2023 SYDNEY, Australia, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced the initiation of the process to obtain a secondary listing on the Nasdaq Capital Market. The Company has filed a registr
